2019-nCoV resistant antibody, preparation and preparation method and application of preparation
The invention is suitable for the technical field of medicine and pharmacy, and provides a 2019-nCoV resistant antibody, a preparation and a preparation method and application of the preparation. Theantibody is specifically bound with an antigen at a spike protein receptor binding region of a 2019-nCoV virus, and the amino acid sequence of the antigen at the spike protein receptor binding regionof the 2019-nCoV virus is shown as a sequence table SEQID NO:1. The preparation containing the antibody is high in titer, has the characteristics of being high in yield, mature in production technology, short in cycle, low in cost, obvious in treatment effects and the like compared with a humanized monoclonal antibody or polyclonal antibody, can effectively neutralize high-titer 2019-nCoV viral particles in bodies of critically ill patients, can also avoid possible antibody-dependent enhancement effects (ADE) to win valuable time for subsequent treatment because purified IgG F(ab)2 does not have Fc fragments, and besides, can perform preventable treatment on suspicious people and close contacts..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 28. Juli Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU MINGYUAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-07-28, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111454354 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005981875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005981875 | ||
| 003 | DE-627 | ||
| 005 | 20230504120126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005981875 | ||
| 035 | |a (EPA)CN111454354 | ||
| 035 | |a (EPA)71676779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU MINGYUAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 2019-nCoV resistant antibody, preparation and preparation method and application of preparation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-07-28, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention is suitable for the technical field of medicine and pharmacy, and provides a 2019-nCoV resistant antibody, a preparation and a preparation method and application of the preparation. Theantibody is specifically bound with an antigen at a spike protein receptor binding region of a 2019-nCoV virus, and the amino acid sequence of the antigen at the spike protein receptor binding regionof the 2019-nCoV virus is shown as a sequence table SEQID NO:1. The preparation containing the antibody is high in titer, has the characteristics of being high in yield, mature in production technology, short in cycle, low in cost, obvious in treatment effects and the like compared with a humanized monoclonal antibody or polyclonal antibody, can effectively neutralize high-titer 2019-nCoV viral particles in bodies of critically ill patients, can also avoid possible antibody-dependent enhancement effects (ADE) to win valuable time for subsequent treatment because purified IgG F(ab)2 does not have Fc fragments, and besides, can perform preventable treatment on suspicious people and close contacts. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12P: Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIU XIAOLEI |4 aut | |
| 700 | 0 | |a SUN YANSONG |4 aut | |
| 700 | 0 | |a GAO YUWEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 28. Juli |
| 773 | 1 | 8 | |g year:2020 |g day:28 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71676779/publication/CN111454354A1?q=CN111454354 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 28 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 28 |c 07 | ||